Joseph M Coney

ORCID

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Venues

International journal of retina and vitreous

Clinical ophthalmology (Auckland, N.Z.)

Ophthalmology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Joseph M Coney, Jasmyne E McCoy, Samriddhi Buxy Sinha, Nina Sonbolian, Lujia Zhou, Thomas P Hull, Shawn A Lewis, David G Miller, Michael A Novak, Scott D Pendergast, Hang Pham, Sean M Platt, Llewelyn J Rao, Jerome P Schartman, Lawrence J Singerman, Richard Donkor, Margaret Fink, Ryan Zubricky, Helene Karcher
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents. Clinical ophthalmology (Auckland, N.Z.) 17 (2023)
Joseph M Coney, Ryan Zubricky, Samriddhi Buxy Sinha, Nina Sonbolian, Lujia Zhou, Thomas P Hull, Shawn A Lewis, David G Miller, Michael A Novak, Scott D Pendergast, Hang Pham, Sean M Platt, Llewelyn J Rao, Jerome P Schartman, Lawrence J Singerman, Richard Donkor, Margaret Fink, Jasmyne McCoy, Helene Karcher
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration. International journal of retina and vitreous 9 (1) (2023)
Joseph M Coney, Ryan Zubricky, Samriddhi Buxy Sinha, Nina Sonbolian, Lujia Zhou, Thomas P Hull, Shawn A Lewis, David G Miller, Michael A Novak, Scott D Pendergast, Hang Pham, Sean M Platt, Llewelyn J Rao, Jerome P Schartman, Lawrence J Singerman, Richard Donkor, Margaret Fink, Jasmyne McCoy, Helene Karcher
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration. International journal of retina and vitreous 9 (1) (2023)
Ryan Zubricky, Jasmyne McCoy, Richard Donkor, David G Miller, Nina Sonbolian, Andrew Heaney, Ver Bilano, Helene Karcher, Joseph M Coney
Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab. Ophthalmology and therapy (2023)

Joseph M Coney.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Joseph M Coney